June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Optimization of humanized C3 rat light damage model for complement therapeutics
Author Affiliations & Notes
  • Adrianna Latuszek
    Ophthalmology, Regeneron Pharmaceuticals Inc, Tarrytown, New York, United States
  • Ming Yuan
    Ophthalmology, Regeneron Pharmaceuticals Inc, Tarrytown, New York, United States
  • Ying Hu
    Ophthalmology, Regeneron Pharmaceuticals Inc, Tarrytown, New York, United States
  • Aixu Sun
    Ophthalmology, Regeneron Pharmaceuticals Inc, Tarrytown, New York, United States
  • rajeevalochan wudali
    Ophthalmology, Regeneron Pharmaceuticals Inc, Tarrytown, New York, United States
  • Henry Chen
    Ophthalmology, Regeneron Pharmaceuticals Inc, Tarrytown, New York, United States
  • Jingtai Cao
    Ophthalmology, Regeneron Pharmaceuticals Inc, Tarrytown, New York, United States
  • Jeffrey Lee
    Ophthalmology, Regeneron Pharmaceuticals Inc, Tarrytown, New York, United States
  • Botir T Sagdullaev
    Ophthalmology, Regeneron Pharmaceuticals Inc, Tarrytown, New York, United States
  • Footnotes
    Commercial Relationships   Adrianna Latuszek Regeneron, Code E (Employment); Ming Yuan Regeneron, Code E (Employment); Ying Hu Regeneron, Code E (Employment); Aixu Sun Regeneron , Code E (Employment); rajeevalochan wudali Regeneron, Code E (Employment); Henry Chen Regeneron, Code E (Employment); Jingtai Cao Regeneron, Code E (Employment); Jeffrey Lee Regeneron, Code E (Employment); Botir Sagdullaev Regeneron , Code E (Employment)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2945. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Adrianna Latuszek, Ming Yuan, Ying Hu, Aixu Sun, rajeevalochan wudali, Henry Chen, Jingtai Cao, Jeffrey Lee, Botir T Sagdullaev; Optimization of humanized C3 rat light damage model for complement therapeutics. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2945.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Complement has been implicated in ocular inflammatory and retinal degenerative diseases. In this study, we optimized humanized C3 rat light damage (LD) as a target engagement model to qualify C3 monoclonal antibodies (mAbs).

Methods : C3 humanized rats received intravitreal injection (25ug in 3ul) of either control or anti-C3 mAb one day before light damage. Rats were then dark adapted overnight. On the day of light damage, pupils were dilated with 1% tropicamide. Animals were light exposed (3000 Lux) for 6hrs using Tek Light T5 blue, fluorescent aquarium light bulb 432W. Animals were euthanized 24, 48 or 72 hours post light damage. Posterior eye cup and serum samples were collected for human C3a ELISA (Quidel) and human C3 ELISA (Abcam), whole rat eyes were collected for C3/C3b immunohistochemistry to evaluate complement activation.

Results : In the posterior eye cup (PEC) of C3 humanized rats, the C3 protein activation peaked at 24 hours and gradually decreased day 2 and 3 post blue light damage as measured by C3a ELISA. However, the serum C3a level remained the same from day 1 to 3 after LD. Different from C3a changes, C3 protein levels in PECs were elevated 24 hours post LD and remained increased until day 3 as measured by C3 ELISA and immunolabeling. C3 mAb delivered either intravitreally or subcutaneously was able to reduce the C3 activation in PEC of C3 humanized rats.

Conclusions : LD induces complement local activation in the eye. This is an effective method to induce complement activation. C3 humanized rat is a useful model for testing human C3 mAb candidates.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×